Skip Navigation


European Heart Journal Advance Access originally published online on December 19, 2008
European Heart Journal 2009 30(5):618-623; doi:10.1093/eurheartj/ehn568
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/5/618    most recent
ehn568v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koeijvoets, K. C.M.C.
Right arrow Articles by Sijbrands, E. J.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koeijvoets, K. C.M.C.
Right arrow Articles by Sijbrands, E. J.G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia

Kristel C.M.C. Koeijvoets1, Simon P. Mooijaart2, Geesje M. Dallinga-Thie3, Joep C. Defesche3, Ewout W. Steyerberg4, Rudi G.J. Westendorp2, John J.P. Kastelein3, P. Martin van Hagen1 and Eric J.G. Sijbrands1,*

1 Department of Internal Medicine, Erasmus Medical Center, PO Box 2040, 3000 AC Rotterdam, The Netherlands
2 Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
3 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
4 Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands

Received 28 April 2008; revised 19 September 2008; accepted 27 November 2008; online publish-ahead-of-print 19 December 2008.

* Corresponding author. Tel: +31 107033283, Fax: +31 107033639, Email: e.sijbrands{at}erasmusmc.nl

Aims: Activation of the complement system seems an important link between inflammation and atherogenesis. The Y402H polymorphism of complement factor H (CFH) has been associated with cardiovascular events, but results are conflicting and possibly modified by age of onset of cardiovascular disease (CVD).

Methods and results: We determined whether or not the Y402H polymorphism influenced CVD risk in a multicentre cohort study involving 2016 unrelated patients with familial hypercholesterolaemia (FH), who have an extremely increased susceptibility to premature CVD. We identified 261 individuals who were homozygous for the polymorphism (CC genotype; 12.9%), 929 individuals who were heterozygous (TC genotype; 46.1%), and 826 individuals carried the wild-type (TT genotype; 41.0%). During 95 115 person years, 644 patients had a cardiovascular event. Carriers of the CC genotype had a decreased risk of CVD (hazard ratio 0.67, 95% confidence interval 0.51–0.87; P = 0.003) relative to the other genotype groups. This association was unaltered after adjustment for clinically relevant cardiovascular risk factors or age effects.

Conclusion: Among patients with severely increased risk of early onset CVD, the Y402H CFH variant was inversely associated with susceptibility to CVD. This suggests that CFH is a modifier gene of CVD.

Key Words: Complement factor H • Cardiovascular disease • Familial hypercholesterolemia • Polymorphism


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.